Form 4: PTC Therapeutics CEO Sells Shares to Cover Tax Obligations

CEO Eric Pauwels sold shares of PTC Therapeutics to cover tax obligations related to the vesting of restricted stock units (RSUs).

Summary

• Eric Pauwels, CEO of PTC Therapeutics, sold shares of common stock on January 7, 2025, and January 8, 2025.
• The sales were executed to cover tax withholding obligations associated with the vesting of RSUs.
• On January 7, 2025, 1,599 shares were sold at a price of $45.34 per share.
• On January 8, 2025, 2,136 shares were sold at a price of $44.50 per share.
• Following these transactions, Pauwels directly owns 86,805 shares of PTC Therapeutics common stock.

Sentiment

Score: 5

Explanation: Neutral sentiment as the document simply reports share sales for tax purposes, a routine financial activity.

Industry Context

Sales of shares to cover tax obligations upon vesting of RSUs are a common practice among executives at publicly traded companies.

Comparison to Industry Standards

• Similar transactions are routinely observed across the pharmaceutical and biotechnology industries, where equity compensation forms a significant part of executive remuneration.
• Companies like Amgen, Gilead Sciences, and Biogen also see similar patterns of share sales by executives to meet tax obligations related to equity awards.

Stakeholder Impact

• The share sales may have a minor, short-term impact on the stock price, but are unlikely to significantly affect long-term shareholder value.

Key Dates